Skip to main content

Table 2 Matched-pair analysis for binominal variables

From: Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation

Variables (+)/(−)a Nr. of analyzed matched pairs in % Concordant pairs Discordant pairs p valueb
Combination PTLD (+) and non-PTLD (+) Combination PTLD (−) and non-PTLD (−) Combination PTLD (−) and non-PTLD (+) Combination PTLD (+) and non-PTLD (−)
Death 100.0 2 22 1 11 0.004
Subsequent re-transplants 100.0 1 26 5 4 0.739
Living Donor 100.0 4 18 5 9 0.285
BMI >30 kg/m2 100.0 0 32 2 1 0.564
Diabetes 100.0 0 32 2 2 1.000
Alcohol abuse 100.0 0 34 2 0 n.d.
Active Smoking 100.0 0 31 2 3 0.655
COPD 100.0 0 35 1 0 n.d.
Recipient EBV IgG at Tx 86.1 12 13 4 2 0.414
Recipient CMV IgG at Tx 91.7 9 15 6 3 0.317
Donor CMV IgG at Tx 97.2 13 8 5 9 0.285
Recipient Anti-HCV at Tx 61.1 0 22 0 0 n.d.
Anti-CMV treatment after Tx 100.0 10 9 7 10 0.467
Ganciclovir/valganciclovir after Tx 100.0 9 11 7 9 0.617
Pre-transplant malignancy 100.0 2 34 0 0 1.000
Pre-transplant HCC 100.0 2 34 0 0 1.000
Non-PTLD malignancy after Tx 100.0 0 31 2 3 0.655
Breast cancer after Tx 100.0 0 35 0 1 n.d.
Pre-transplant dialysis 100.0 12 20 2 2 1.000
Donor HLA A26, B38 75.0 0 25 0 2 n.d.
Donor HLA A1 75.0 1 15 5 6 0.763
Donor HLA B8 75.0 1 21 3 2 0.655
Donor HLA DR3 75.0 1 20 4 2 0.414
Recipient HLA A26, B38 52.8 0 18 0 1 n.d.
Recipient HLA A2 52.8 6 2 10 1 0.007
Recipient HLA A11 52.8 0 15 3 1 0.317
Recipient HLA B5 52.8 0 15 2 2 1.000
Recipient HLA B18 52.8 0 16 3 0 n.d.
Recipient HLA B21 52.8 0 18 1 0 n.d.
Recipient HLA B35 52.8 1 12 4 2 0.414
Recipient HLA A3 52.8 1 10 4 4 1.000
Recipient HLA DR27 52.8 0 19 0 0 n.d.
HLA A locus mismatching 47.2 7 2 3 5 0.480
HLA B locus mismatching 47.2 10 0 3 4 0.706
HLA DR locus mismatching 47.2 12 2 2 1 0.564
Anti-thymocyte globulin after Tx 86.1 0 30 1 0 n.d.
Basiliximab therapy after Tx 86.1 6 11 7 7 1.000
Daclizumab therapy after Tx 86.1 0 29 1 1 1.000
Tacrolimusc after Tx 100.0 5 18 3 10 0.052
Ciclosporinec after Tx 100.0 17 5 10 4 0.109
MMFc after Tx 100.0 10 15 5 6 0.763
Myforticc after Tx 100.0 0 35 0 1 n.d.
Steroidsc after Tx 100.0 32 1 1 2 0.564
Sirolimusc after Tx 100.0 0 34 1 1 1.000
Everolimusc after Tx 100.0 0 34 1 1 1.000
Azathioprinc after Tx 100.0 1 33 2 0 0.157
Tacrolimus at PTLDd 100.0 7 14 6 9 0.439
Ciclosporine at PTLDd 100.0 12 12 9 3 0.083
CNI-free treatment at PTLDd 100.0 1 30 1 4 0.180
  1. Summarized are the results of matched-pair analysis for binominal variables. Their distribution in concordant and discordant pairs in matched-pair analysis is shown
  2. a(+)/(−)-classifiers identify yes/no or positive/negative variables
  3. bMcNemar’s test for binary variables
  4. cAt hospital discharge
  5. dDiagnosis or equivalent date in the non-PTLD group
  6. Tx transplantation, COPD chronic obstructive pulmonary disease, BMI body mass index, EBV Epstein-Barr virus, CMV cytomegalovirus, HCC hepatocellular carcinoma, HCV hepatits C virus, HLA human leukocyte antigen, MMF mycophenolat mofetil, CNI calcineurin inhibitor, n.d. p value not determined due to zero cases within pairs (McNemar’s test)